OpGen, Inc. (OPGN) :0.6300+0.0600 (+10.53%)
52 Week Range 0.5400 - 13.6000
Following final assembly and successful testing, a batch of ten Unyvero A30 instrument systems has been received
Latest C-Series Unyvero A30 instruments optimized for series production and clinical trials
ROCKVILLE, Md., June 22, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported that its German subsidiary, Curetis GmbH, has received the full set of ten Unyvero A30 C-Series instruments, which have been assembled by its development partner, DMTPe, in Germany. The instruments have successfully passed electrical and functional testing and will allow rapid sample-to-answer molecular testing with numerous chemistries and assay formats.
These C-Series instruments incorporate all learnings from extensive testing of the 10 B-Series instruments over the past 12 months. The C-Series instruments have been optimized and improved for manufacturability, serviceability and robustness. They have also been optimized for extended lifetime of all key moving parts inside the instruments, as well as cost of goods in the manufacturing process of these A30 instruments.
Andreas Boos, CTO of Curetis and program lead of the Unyvero A30 platform project commented: “We are excited to have taken possession of this newest batch of instruments. With all of the improvements made to date, this is now very close to the final release version of the product. We intend to use the A30 C-Series instruments in all further product development and clinical trials as well as regulatory submissions for our application cartridges on the A30 system.” Mr. Boos added that, “all of our ten B-Series instruments have also been upgraded to this latest standard to plan for sufficient A30 instruments to be available for the continued development of our own assays and cartridges in house, and for collaborative projects such as the FIND R&D collaboration which aims to bring an A30 platform and antimicrobial resistance (AMR) test from blood cultures to low and middle income countries, as well as for other R&D collaboration projects funded by third party partners.”
About OpGen, Inc.
OpGen, Inc. (Rockville, MD, U.S.A.) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s current product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction including ARESiss, ARESid, ARESasp, and AREScloud, as well as the Curetis CE-IVD-marked PCR-based SARS-CoV-2 test kit.
For more information, please visit www.opgen.com.
time for a strong recovery:
Jun 21, 2023 0.5900 0.6300 0.5400 0.6300 0.6300 364,754
Jun 19, 2023 0.6000 0.6300 0.5400 0.6300 0.6300 527,300
Jun 12, 2023 0.6400 0.7200 0.5800 0.6000 0.6000 1,968,700
Jun 05, 2023 0.7000 0.7200 0.5600 0.6000 0.6000 413,900
May 29, 2023 0.7100 0.7700 0.6900 0.7000 0.7000 357,600
May 22, 2023 0.7500 0.8000 0.6890 0.7050 0.7050 413,300
May 15, 2023 0.7700 0.7760 0.6440 0.7460 0.7460 420,900
May 08, 2023 0.7900 0.8680 0.7100 0.7520 0.7520 535,100
May 01, 2023 0.7600 0.8080 0.5500 0.7640 0.7640 1,197,700
Apr 24, 2023 0.9600 0.9930 0.7390 0.7940 0.7940 5,012,100
Apr 17, 2023 1.1400 1.2700 0.9340 0.9800 0.9800 2,665,500
Apr 10, 2023 1.2800 1.3000 1.0900 1.1400 1.1400 632,200
Apr 03, 2023 1.3400 1.3800 1.2900 1.3100 1.3100 512,800
Mar 27, 2023 1.5300 1.5600 1.1500 1.3300 1.3300 2,066,500
Mar 20, 2023 1.4800 1.6000 1.3100 1.4900 1.4900 2,480,700
Mar 13, 2023 1.0600 1.4700 0.9860 1.4700 1.4700 5,374,700
Mar 06, 2023 1.1100 1.2470 0.9300 1.1000 1.1000 3,861,800
Feb 27, 2023 1.0200 1.1300 1.0000 1.1000 1.1000 795,600
Feb 20, 2023 1.1800 1.2900 0.9900 1.0300 1.0300 1,145,700
Feb 13, 2023 1.4400 1.4400 0.9800 1.1800 1.1800 2,933,200
Feb 06, 2023 1.7600 2.0500 1.4000 1.4100 1.4100 4,334,900
Jan 30, 2023 1.9200 2.0800 1.6600 1.7400 1.7400 1,635,600
Jan 23, 2023 2.2700 2.3100 1.8200 1.9200 1.9200 2,118,100
Jan 16, 2023 2.6100 2.7210 2.2300 2.3000 2.3000 647,800
Jan 09, 2023 2.3900 2.7300 2.2200 2.6000 2.6000 1,294,300
Jan 02, 2023 2.8000 3.8000 2.5000 2.6500 2.6500 1,347,185
Dec 26, 2022 2.5800 3.2000 2.2200 2.8200 2.8200 505,600
Dec 19, 2022 2.8200 3.0000 2.4000 2.6000 2.6000 592,145
Dec 12, 2022 2.4200 9.0600 2.3400 2.6200 2.6200 13,543,83
